CytomX Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
CytomX Therapeutics, Inc. (CTMX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.67 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- CytomX Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.62.
- CytomX Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.57.
- CytomX Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- CytomX Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.36, a 57.10% decline year-over-year.
- CytomX Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $1.57, a 0.63% decline from fiscal 2024.
- CytomX Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $1.58, a 0.64% increase from fiscal 2023.
- CytomX Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $1.57, a 60.20% increase from fiscal 2022.
- CytomX Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.98, a 63.70% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.67 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $1.62 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $1.57 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $1.57 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $1.47 10-Q · filed 2025-08-07 | ||||
| 2024-12-31 | $1.58 10-K · filed 2025-03-06 | ||||
| 2024-09-30 | $1.58 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $1.58 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $1.57 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $1.57 10-K · filed 2024-03-11 | ||||
| 2023-09-30 | $1.57 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $1.57 10-Q · filed 2023-08-08 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $0.98 10-K · filed 2023-03-27 | ||||
| 2022-09-30 | $0.98 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $0.98 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $1.36 10-Q · filed 2022-05-05 | ||||
| 2021-12-31 | $2.70 10-K/A · filed 2023-03-27 | ||||
| 2021-09-30 | $2.69 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $3.06 10-Q · filed 2021-08-05 | ||||
| 2021-03-31 | $3.17 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | $4.58 10-K · filed 2021-02-24 | ||||
| 2020-09-30 | $5.58 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $5.61 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $5.45 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $4.30 10-K · filed 2020-02-27 | ||||
| 2019-09-30 | $5.00 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | $5.55 10-Q · filed 2019-08-07 | ||||
| 2019-03-31 | $6.24 10-Q · filed 2019-05-09 | ||||
| 2018-12-31 | $6.17 10-K · filed 2020-02-27 | $6.17 10-K · filed 2019-02-27 | |||
| 2018-09-30 | $6.25 10-Q · filed 2018-11-06 | ||||
| 2018-06-30 | $5.78 10-Q · filed 2018-08-08 | ||||
| 2018-03-31 | $6.12 10-Q · filed 2018-05-09 | ||||
| 2017-12-31 | $4.14 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $4.17 10-Q · filed 2017-11-07 | ||||
| 2017-06-30 | $3.86 10-Q · filed 2017-08-07 | ||||
| 2017-03-31 | $3.89 10-Q · filed 2017-05-05 | ||||
| 2016-12-31 | $1.55 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $1.23 10-Q · filed 2016-11-03 | ||||
| 2016-06-30 | $1.24 10-Q · filed 2016-08-03 | ||||
| 2016-03-31 | $1.12 10-Q · filed 2016-05-06 | ||||
| 2015-12-31 | $1.51 10-K · filed 2018-03-07 | ||||
| 2015-09-30 | $1.29 10-Q · filed 2015-11-23 | ||||
| 2014-12-31 | $1.26 10-K · filed 2017-03-02 | ||||
| 2013-12-31 | $1.13 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |